💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Technetium Tc 99M Tilmanocept

CHEMBL2108726 Phase 4 Aprovado Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Technetium Tc 99m tilmanocept is a radiolabeled mannose receptor (CD206)-targeted sentinel lymph node mapping agent consisting of a dextran backbone conjugated with multiple mannose residues and DTPA chelators, providing highly specific and rapid binding to macrophages and dendritic cells in sentinel lymph nodes. It is approved for intraoperative sentinel lymph node identification in breast cancer, melanoma, and head and neck cancer to guide surgical staging. Its receptor-mediated retention in sentinel nodes is superior to passive colloidal accumulation, reducing the risk of false-negative results.

Áreas Terapêuticas

Melanoma Rheumatoid Arthritis Breast Cancer Colorectal Cancer

Mecanismo de Ação

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Technetium Tc 99m tilmanocept is a radiolabeled mannose receptor (CD206)-targeted sentinel lymph node mapping agent consisting of a dextran backbone conjugated with multiple mannose residues and DTPA chelators, providing highly specific and rapid binding to macrophages and dendritic cells in sentinel lymph nodes. It is approved for intraoperative sentinel lymph node identification in breast cancer, melanoma, and head and neck cancer to guide surgical staging. Its receptor-mediated retention in sentinel nodes is superior to passive colloidal accumulation, reducing the risk …

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Yes, Technetium Tc 99M Tilmanocept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108726. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.